Aquestive Therapeutics Highlights Anaphylm Review, Launch Plans and $90.3M Cash Position
Aquestive Therapeutics reported FDA acceptance of Anaphylm's NDA resubmission with a March 2027 PDUFA goal date. The company plans regulatory filings in Canada and the EU by 2027. As of September 2026, cash reserves were $90.3 million, with up to $95 million in additional funding possible. A U.S. launch with 65-80 sales reps is planned if approved.
How this was made

The 30-second read
Why it matters
The FDA acceptance moves the product closer to market, potentially unlocking revenue and justifying the $90M cash position.
Market read
Regulatory milestone likely triggers short‑term buying interest and sets a timeline for future catalysts.
What to watch
The company still needs to secure additional funding and navigate foreign filings, which could delay commercialization.
Background
Aquestive Therapeutics (AQST) is a clinical‑stage biotech developing Anaphylm for rare allergic conditions.
Ticker impact
FDA accepted Anaphylm's NDA resubmission and set a March 2027 PDUFA target, a material regulatory milestone for the company.
upward pressure as investors price in potential approval and future sales.
An FDA acceptance is a key catalyst for biotech valuations; the market typically reacts positively to such milestones.
Market effects
May boost sentiment for the broader rare‑disease biotech sector.
Limited to U.S. biotech investors.
Minor, confined to specialty pharma space.
Counterpoint
If the FDA later requests additional data, the initial acceptance could be overstated.
Key entities
- companyAquestive Therapeutics
Biotech firm developing Anaphylm.
- regulatorFDA
U.S. Food and Drug Administration.

